Viatris Inc., a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.